Report on the Public roundtable into Adhesive Arachnoiditis

GlaxoSmithKline (GSK) welcomes the report on the roundtable into adhesive arachnoiditis provided by the Standing Committee on Health and Ageing released today.

Representatives from GSK provided information to the roundtable through an ‘in- camera’ basis.

We are currently considering the information within the report, including recommendation one, which encourages GSK to establish a Charitable Foundation to assist sufferers of adhesive arachnoiditis.

GSK has the utmost sympathy for the people who have been, and are, afflicted by arachnoiditis. Arachnoiditis is a complex condition that may be caused by a number of conditions such as spinal infections, surgery and trauma.

GSK believes that it acted responsibly at all times in relation to the supply of Myodil. Glaxo supplied this diagnostic product with the information available at that time to meet the needs of a very knowledgeable and specialist medical profession for many years, until it was superseded by newer products and technology.

GlaxoSmithKline is a global research-based pharmaceutical and healthcare company with a proud history in Australia dating back to 1886. Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer.